<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03746535</url>
  </required_header>
  <id_info>
    <org_study_id>2000022193</org_study_id>
    <nct_id>NCT03746535</nct_id>
  </id_info>
  <brief_title>Cardiovascular Disease Risk in Women With Endometriosis</brief_title>
  <official_title>Cardiovascular Disease Risk in Women With Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the hypothesis that estrogen suppression impairs endothelial dysfunction in
      endometriosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our scientific premise is that in women with endometriosis, elevated cardiovascular disease
      risk is the result of endothelial dysfunction and chronic systemic inflammation through
      lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) receptor activation. This
      cardiovascular disease risk is exacerbated by standard estrogen suppression treatments.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 cohort clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>no masking, all subjects have endometriosis</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Flow Mediated Vasodilation Microvascular skin blood flow analysis</measure>
    <time_frame>2 minutes</time_frame>
    <description>Blood flow velocity will be measured using the Sonoscope S2 ultrasound imaging system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow Mediated Vasodilation Microvascular skin blood flow analysis</measure>
    <time_frame>2 minutes</time_frame>
    <description>Brachial artery diameter will be measured using the Sonoscope S2 ultrasound imaging system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microdialysis perfusions</measure>
    <time_frame>15 minutes</time_frame>
    <description>Following recovery from the microdialysis probe insertions we will measure resting skin blood flow (SkBF).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>patients without endometriosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control subjects will be healthy women, with regular menses every 26-34 days. Subjects will be excluded if they have any symptoms of endometriosis, including severe dysmenorrhea or progressive cyclic pelvic pain or prior surgery showing evidence of endometriosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with endometriosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endometriosis will be diagnosed by history of the disease seen at the time of prior surgery or will be diagnosed by classic clinical symptoms of the disease (cyclic progressive pelvic pain) using prior surgical report reviewed by Dr. Taylor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix Acetate</intervention_name>
    <description>Ganirelix acetate alone, 250 Î¼g/day in 0.5 ml normal saline,</description>
    <arm_group_label>patients with endometriosis</arm_group_label>
    <arm_group_label>patients without endometriosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Young women between the ages of 18 and 45 years (Controls);

          -  Young women between the ages of 18 and 45 years with endometriosis.

        Exclusion Criteria:

          -  Subjects who smoke

          -  Subjects who have diabetes,

          -  Subjects with sleep apnea or BP&gt;140/90 will be excluded.

          -  Women with endometriosis and severe acute pain requiring immediate treatment will be
             excluded.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Stachenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina Stachenfeld, MD</last_name>
    <phone>203-562-9901</phone>
    <phone_ext>219</phone_ext>
    <email>nina.stachenfeld@yale.edu</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

